Filter posts

Uniting To Accelerate Pediatric Medicine

Drug companies inherently absorb significant risk when developing compounds and biologics for clinical use. A …

New CDC Report on Alarming Rates of Antibiotic-Resistant Infections

Every year in the United States, 2 million people acquire an antibiotic-resistant infection. Of those, at …

Putting Patients First: Paving a Path to Useful CER

Comparative effectiveness research (CER) has the potential to improve health outcomes by helping people make …

FDA Consumer Update: Advances in Saving Lives with Blood

Every two seconds in the U.S., someone needs a blood transfusion or blood product—people of …

Exploring New Solutions For Neglected Diseases in Developing Countries

On Tuesday, BIO Ventures for Global Health (BVGH) announced the completion of the 30th research agreement …

CTTI: Use of Central IRBs in Multi-Center Trials to Streamline Clinical Research

Multi-center clinical trials can provide high-quality, statistically-sound evidence to answer medical questions. Earlier this year, …

New PhRMA Report: Nearly 300 Vaccines Currently in Development

Today, the Pharmaceutical Research and Manufacturers of America released a report, Medicines in Development: Vaccines …

NCATS R&D Day Aimed At Linking Investors to Preclinical Drug Development Projects

On behalf of the National Center for Advancing Translational Sciences (NCATS), I invite BIO stakeholders …

Driving Innovation in Breast Cancer: Startup Challenge

The Avon Foundation (AF), National Institutes of Health National Cancer Institute (NCI) and Center for …

State Legislation Needed For Substitution of Interchangeable Biologics

A great deal of the media coverage relating to California’s Senate Bill 598  neglects to …